Boehringer Ingelheim and Eli Lilly have partnered with the University of Oxford to assess the effects of Jardiance on disease progression and occurrence of cardiovascular death in chronic kidney disease patients.

Jardiance is a prescription medicine currently indicated to minimise blood sugar and risk of cardiovascular death in adults with type 2 diabetes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug will be trialled in approximately 5,000 patients with established chronic kidney disease, both with and without diabetes.

The primary outcome of the study is to assess the effect of Jardiance on time to clinically relevant kidney disease progression or cardiovascular death. The study will be part of the empagliflozin clinical development programme, the largest clinical development programme of its kind.

Boehringer Ingelheim pharmaceuticals clinical development and medical affairs primary care vice-president Thomas Seck said: “Boehringer Ingelheim and Lilly are committed to exploring how Jardiance can potentially fill gaps where unmet treatment needs exist.

“Boehringer Ingelheim and Lilly are committed to exploring how Jardiance can potentially fill gaps where unmet treatment needs exist.”

“Given the institution’s knowledge and history of prestigious research in chronic kidney disease, we are excited to collaborate with the University of Oxford on this initiative to help address a pressing need for people with chronic kidney disease.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the academic collaboration, the companies will sponsor the EMPA-KIDNEY trial, which will be carried out by the university’s Medical Research Council Population Health Research Unit in alliance with the US-based Duke Clinical Research Institute.

Lilly diabetes product development vice-president Jeff Emmick said: “The EMPA-KIDNEY study, which will build on results of the EMPA-REG OUTCOME trial, will continue to expand our understanding of how Jardiance can impact the lives of a broad range of people with and without diabetes.

“We look forward to this new partnership and the opportunity to follow the progress of the EMPA-KIDNEY study.”